

Laia Par

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4743437/laia-pare-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25
papers

613
citations

10
h-index

24
g-index

27
ext. papers

1,014
ext. citations

7.8
avg, IF

3.29
L-index

#	Paper	IF	Citations
25	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 545-554	21.7	175
24	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 2213-2221	10.1	109
23	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. <i>JAMA Oncology</i> , 2016 , 2, 1287-1294	13.4	65
22	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 1	7.8	54
21	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 33-43	21.7	52
20	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 46-54	9.7	48
19	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. <i>International Journal of Cancer</i> , 2020 , 146, 262-271	7.5	17
18	Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1458-1467	2.2	15
17	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. <i>Oncologist</i> , 2019 , 24, 893-900	5.7	12
16	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. <i>Breast Cancer Research</i> , 2019 , 21, 108	8.3	11
15	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 21930-21937	3.3	10
14	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
13	PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. <i>Frontiers in Oncology</i> , 2019 , 9, 707	5.3	7
12	Development and validation for research assessment of Oncotype DX [®] Breast Recurrence Score, EndoPredict [®] and Prosigna [®] . <i>Npj Breast Cancer</i> , 2021 , 7, 15	7.8	6
11	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 507-507	2.2	4
10	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 303	5.3	3
9	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.. <i>EBioMedicine</i> , 2022 , 75, 103801	8.8	3

8	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2021 ,	7.9	3
7	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1025-1025	2.2	2
6	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6141-6148	12.9	2
5	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021 , 7, 73	7.8	2
4	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 12	7.8	2
3	Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 575-575	2.2	1
2	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. <i>Frontiers in Immunology</i> , 2021 , 12, 792609	8.4	
1	Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16579-e16579	2.2	